代谢性脑血管病：概念、方法、挑战和未来方向

doi:10.3969/j.issn.1673-5765.2023.06.001

摘要/Abstract

摘要： 代谢危险因素是导致心脑血管病的重要原因。目前代谢性心血管病已有明确的概念和综合管理体系，而在我国发病率高、异质性强的脑血管病领域，尚未形成统一的代谢性脑血管病的定义和概念。本文综述脑血管病的代谢危险因素，提出代谢性脑血管病的概念和分类，阐述基于多组学技术的多学科、多器官水平的研究方法，介绍近年来涌现的具有心血管获益的代谢药物的特点及未来面临的挑战和研究方向，为代谢性脑血管病的综合管理提供理论依据。

关键词: 代谢性脑血管病; 脑血管代谢风险; 生物标志物; 多学科综合管理

Abstract: Metabolic risk factors are important causes of cardiovascular and cerebrovascular diseases. There is already a definite concept and comprehensive management system for cardio-metabolic disease. While the incidence rate of stroke is higher and exhibit greater heterogeneity in China, and lacks a concept of cerebro-metabolic disease currently. Therefore, we reviewed the metabolic risk factors of stroke, proposed the concept and classification of cerebro-metabolic disease, elucidated the interdisciplinary and multi-organ level research methods based on multi-omics technology, introduced the characteristics of recently emerged metabolic drugs with cardiovascular benefits and the challenges and future directions. We aimed to provide a theoretical basis for the comprehensive management of cerebro-metabolic disease.

Key words: Cerebro-metabolic disease; Cerebro-metabolic risk; Biomarker; Comprehensive multidisciplinary management

许杰, 王拥军. 代谢性脑血管病：概念、方法、挑战和未来方向[J]. 中国卒中杂志, 2023, 18(06): 617-627.

XU Jie, WANG Yongjun. Cerebro-Metabolic Disease: Concept, Method, Challenge and Future Directions[J]. Chinese Journal of Stroke, 2023, 18(06): 617-627.

参考文献

[1] GBD 2016 Lifetime Risk Of Stroke Collaborators. Global，regional，and country-specific lifetime risks of stroke，1990 and 2016[J]. N Engl J Med，2018，379（25）：2429-2437.
[2] TSAO C W，ADAY A W，ALMARZOOQ Z I，et al. Heart disease and stroke statistics-2022 update：a report from the American Heart Association[J/OL]. Circulation，2022，145（8）：e153-e639[2023-02-16]. https://doi.org/10.1161/CIR.0000000000001052.
[3] TSAI C F，THOMAS B，SUDLOW C L. Epidemiology of stroke and its subtypes in Chinese vs. white populations：a systematic review[J]. Neurology，2013，81（3）：264-272.
[4] 中国血脂管理指南修订联合专家委员会. 中国血脂管理指南（2023年）[J]. 中国循环杂志，2023，38（3）：237-271.
[5] MACH F，BAIGENT C，CATAPANO A L，et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias：lipid modification to reduce cardiovascular risk[J]. Eur Heart J，2020，41（1）：111-188.
[6] VISSEREN F L J，MACH F，SMULDERS Y M，et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice[J]. Eur J Prev Cardiol，2022，29（1）：5-115.
[7] NAVARESE E P，ROBINSON J G，KOWALEWSKI M，et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering：a systematic review and meta-analysis[J]. JAMA，2018，319（15）：1566-1579.
[8] Cholesterol Treatment Trialists'（CTT）Collaboration. Efficacy and safety of LDL-lowering therapy among men and women：meta-analysis of individual data from 174，000 participants in 27 randomised trials[J]. Lancet，2015，385（9976）：1397-1405.
[9] SILVERMAN M G，FERENCE B A，IM K，et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions：a systematic review and meta-analysis[J]. JAMA，2016，316（12）：1289-1297.
[10] AMARENCO P，BOGOUSSLAVSKY J，CALLAHAN A 3rd，et al. High-dose atorvastatin after stroke or transient ischemic attack[J]. N Engl J Med，2006，355（6）：549-559.
[11] AMARENCO P，KIM J S，LABREUCHE J，et al. A Comparison of two LDL cholesterol targets after ischemic stroke[J]. N Engl J Med，2020，382（1）：9.
[12] SABATINE M S，GIUGLIANO R P，KEECH A C，et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med，2017，376（18）：1713-1722.
[13] SCHWARTZ G G，STEG P G，SZAREK M，et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome[J]. N Engl J Med，2018，379（22）：2097-2107.
[14] 王拥军，李子孝，谷鸿秋，等. 中国卒中报告2020（中文版）（1）[J]. 中国卒中杂志，2022，17（5）：433-447.
[15] JIA Q，ZHENG H G，ZHAO X Q，et al. Abnormal glucose regulation in patients with acute stroke across China：prevalence and baseline patient characteristics[J]. Stroke，2012，43（3）：650-657.
[16] HOLMAN R R，PAUL S K，BETHEL M A，et al. 10-year follow-up of intensive glucose control in type 2 diabetes[J]. N Engl J Med，2008，359（15）：1577-1589.
[17] ZINMAN B，WANNER C，LACHIN J M，et al. Empagliflozin，cardiovascular outcomes，and mortality in type 2 diabetes[J]. N Engl J Med，2015，373（22）：2117-2128.
[18] MARSO S P，DANIELS G H，BROWN-FRANDSEN K，et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med，2016，375（4）：311-322.
[19] MARSO S P，BAIN S C，CONSOLI A，et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med，2016，375（19）：1834-1844.
[20] KERNAN W N，VISCOLI C M，FURIE K L，et al. Pioglitazone after ischemic stroke or transient ischemic attack[J]. N Engl J Med，2016，374（14）：1321-1331.
[21] O'DONNELL M J，CHIN S L，RANGARAJAN S，et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries（INTERSTROKE）：a case-control study[J]. Lancet，2016，388（10046）：761-775.
[22] ZHOU M G，WANG H D，ZENG X Y，et al. Mortality，morbidity，and risk factors in China and its provinces，1990-2017：a systematic analysis for the global burden of disease study 2017[J]. Lancet，2019，394（10204）：1145-1158.
[23] LEWINGTON S，CLARKE R，QIZILBASH N，et al. Age-specific relevance of usual blood pressure to vascular mortality：a meta-analysis of individual data for one million adults in 61 prospective studies[J]. Lancet，2002，360（9349）：1903-1913.
[24] COLLINS R，PETO R，MACMAHON S，et al. Blood pressure，stroke，and coronary heart disease. Part 2，Short-term reductions in blood pressure：overview of randomised drug trials in their epidemiological context[J]. Lancet，1990，335（8693）：827-838.
[25] PATS COLLABORATING GROUP. Post-stroke antihypertensive treatment study. A preliminary result[J]. Chin Med J（Engl），1995，108（9）：710-717.
[26] Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6，105 individuals with previous stroke or transient ischaemic attack[J]. Lancet，2001，358（9287）：1033-1041.
[27] ANDERSON C S，HUANG Y，WANG J G，et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial（INTERACT）：a randomised pilot trial[J]. Lancet Neurol，2008，7（5）：391-399.
[28] ANDERSON C S，HEELEY E，HUANG Y，et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage[J]. N Engl J Med，2013，368（25）：2355-2365.
[29] MA L，HU X，SONG L L，et al. The third intensive care bundle with blood pressure reduction in acute cerebral haemorrhage trial（INTERACT3）：an international，stepped wedge cluster randomised controlled trial[J/OL]. Lancet，2023，S0140-6736（23）00806-1[2023-02-16]. https://doi.org/10.1016/S0140-6736（23）00806-1.
[30] DRAWZ P E，PAJEWSKI N M，BATES J T，et al. Effect of intensive versus standard clinic-based hypertension management on ambulatory blood pressure：results from the SPRINT（systolic blood pressure intervention trial）ambulatory blood pressure study[J]. Hypertension，2017，69（1）：42-50.
[31] SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke：the SPS3 randomised trial[J]. Lancet，2013，382（9891）：507-515.
[32] WARTOLOWSKA K A，WEBB A J S. Midlife blood pressure is associated with the severity of white matter hyperintensities：analysis of the UK Biobank cohort study[J]. Eur Heart J，2021，42（7）：750-757.
[33] 吴超群，李希，路甲鹏，等. 中国居民心血管疾病危险因素分布报告[J]. 中国循环杂志，2021，36（1）：4-13
[34] KIVIMÄKI M，KUOSMA E，FERRIE J E，et al. Overweight，obesity，and risk of cardiometabolic multimorbidity：pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe[J/OL]. Lancet Public Health，2017，2（6）：e277-e285[2023-02-20]. https://doi.org/10.1016/S2468-2667（17）30074-9.
[35] JAYEDI A，SOLTANI S，ZARGAR M S，et al. Central fatness and risk of all cause mortality：systematic review and dose-response meta-analysis of 72 prospective cohort studies[J/OL]. BMJ，2020，370：m3324[2023-02-20]. https://doi.org/10.1136/bmj.m3324.
[36] ECKEL N，LI Y，KUXHAUS O，et al. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women（the Nurses' Health Study）：30 year follow-up from a prospective cohort study[J]. Lancet Diabetes Endocrinol，2018，6（9）：714-724.
[37] TOWFIGHI A，OVBIAGELE B. The impact of body mass index on mortality after stroke[J]. Stroke，2009，40（8）：2704-2708.
[38] LI J J，ZHAO X Q，MENG X，et al. High-sensitive c-reactive protein predicts recurrent stroke and poor functional outcome：subanalysis of the clopidogrel in high-risk patients with acute nondisabling cerebrovascular events trial[J]. Stroke，2016，47（8）：2025-2030.
[39] RIDKER P M，BHATT D L，PRADHAN A D，et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy：a collaborative analysis of three randomised trials[J]. Lancet，2023，401（10384）：1293-1301.
[40] VAN DIJK E J，PRINS N D，VERMEER S E，et al. C-reactive protein and cerebral small-vessel disease：the rotterdam scan study[J]. Circulation，2005，112（6）：900-905.
[41] RIDKER P M，EVERETT B M，THUREN T，et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med，2017，377（12）：1119-1131.
[42] TU W J，YAN F，CHAO B H，et al. Status of hyperhomocysteinemia in China：results from the China Stroke High-risk Population Screening Program，2018[J]. Front Med，2021，15（6）：903-912.
[43] WALD D S，LAW M，MORRIS J K. Homocysteine and cardiovascular disease：evidence on causality from a meta-analysis[J]. BMJ，2002，325（7374）：1202.
[44] HUO Y，LI J P，QIN X H，et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China：the CSPPT randomized clinical trial[J]. JAMA，2015，313（13）：1325-1335.
[45] TOOLE J F，MALINOW M R，CHAMBLESS L E，et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke，myocardial infarction，and death：the vitamin intervention for stroke prevention（VISP）randomized controlled trial[J]. JAMA，2004，291（5）：565-575.
[46] Vitatops Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke in the vitamins to prevent Stroke（VITATOPS）trial：a randomised，double-blind，parallel，placebo-controlled trial[J]. Lancet Neurol，2010，9（9）：855-865.
[47] ZHONG C K，ZHONG X Y，XU T，et al. Sex-specific relationship between serum uric acid and risk of stroke：a dose-response meta-analysis of prospective studies[J/OL]. J Am Heart Assoc，2017，6（4）：e005042[2023-02-20]. https://doi.org/10.1161/JAHA.116.005042.
[48] WEIR C J，MUIR S W，WALTERS M R，et al. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke[J]. Stroke，2003，34（8）：1951-1956.
[49] BOS M J，KOUDSTAAL P J，HOFMAN A，et al. Uric acid is a risk factor for myocardial infarction and stroke：the rotterdam study[J]. Stroke，2006，37（6）：1503-1507.
[50] AMARO S，LAREDO C，RENÚ A，et al. Uric acid therapy prevents early ischemic stroke progression：a tertiary analysis of the URICO-ICTUS trial（efficacy study of combined treatment with uric acid and r-tpa in acute ischemic stroke）[J]. Stroke，2016，47（11）：2874-2876.
[51] LLULL L，LAREDO C，RENÚ A，et al. Uric acid therapy improves clinical outcome in women with acute ischemic stroke[J]. Stroke，2015，46（8）：2162-2167.
[52] KOETH R A，WANG Z，LEVISON B S，et al. Intestinal microbiota metabolism of L-carnitine，a nutrient in red meat，promotes atherosclerosis[J]. Nat Med，2013，19（5）：576-585.
[53] ZHU W F，GREGORY J C，ORG E，et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk[J]. Cell，2016，165（1）：111-124.
[54] SCHIATTARELLA G G，SANNINO A，TOSCANO E，et al. Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker：a systematic review and dose-response meta-analysis[J]. Eur Heart J，2017，38（39）：2948-2956.
[55] MISHRA A，MALIK R，HACHIYA T，et al. Stroke genetics informs drug discovery and risk prediction across ancestries[J]. Nature，2022，611（7934）：115-123.
[56] FRANZÉN O，ERMEL R，COHAIN A，et al. Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases[J]. Science，2016，353（6301）：827-830.
[57] KOPLEV S，SELDIN M，SUKHAVASI K，et al. A mechanistic framework for cardiometabolic and coronary artery diseases[J]. Nat Cardiovasc Res，2022，1（1）：85-100.
[58] NURMOHAMED N S，BELO PEREIRA J P，HOOGEVEEN R M，et al. Targeted proteomics improves cardiovascular risk prediction in secondary prevention[J]. Eur Heart J，2022，43（16）：1569-1577.
[59] LAAKSONEN R，EKROOS K，SYSI-AHO M，et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol[J]. Eur Heart J，2016，37（25）：1967-1976.
[60] WANG Z，KLIPFELL E，BENNETT B J，et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease[J]. Nature，2011，472（7341）：57-63.
[61] XU J，CHENG A C，SONG B，et al. Trimethylamine N-Oxide and stroke recurrence depends on ischemic stroke subtypes[J]. Stroke，2022，53（4）：1207-1215.
[62] LEWIS G F，CARPENTIER A，ADELI K，et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes[J]. Endocr Rev，2002，23（2）：201-229.
[63] SEMOVA I，LEVENSON A E，KRAWCZYK J，et al. Insulin prevents hypercholesterolemia by suppressing 12 alpha-hydroxylated bile acids[J]. Circulation，2022，145（13）：969-982.
[64] HOTAMISLIGIL G S. Inflammation and metabolic disorders[J]. Nature，2006，444（7121）：860-867.
[65] PRIEST C，TONTONOZ P. Inter-organ cross-talk in metabolic syndrome[J]. Nat Metab，2019，1（12）：1177-1188.
[66] FRANCQUE S，SZABO G，ABDELMALEK M F，et al. Nonalcoholic steatohepatitis：the role of peroxisome proliferator-activated receptors[J]. Nat Rev Gastroenterol Hepatol，2021，18（1）：24-39.
[67] SIMON T G，ROELSTRAETE B，HAGSTROM H，et al. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events：results from a nationwide histology cohort[J]. Gut，2022，71（9）：1867-1875.
[68] TARGHER G，BYRNE C D，TILG H. NAFLD and increased risk of cardiovascular disease：clinical associations，pathophysiological mechanisms and pharmacological implications[J]. Gut，2020，69（9）：1691-1705.
[69] GLUCHOWSKI N L，BECUWE M，WALTHER T C，et al. Lipid droplets and liver disease：from basic biology to clinical implications[J]. Nat Rev Gastroenterol Hepatol，2017，14（6）：343-355.
[70] US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults：us preventive services task force recommendation statement[J]. JAMA，2022，328（8）：746-753.
[71] NORDESTGAARD B G，CHAPMAN M J，RAY K，et al. Lipoprotein（a）as a cardiovascular risk factor：current status[J]. Eur Heart J，2010，31（23）：2844-2853.
[72] HABERMAN Y，IQBAL N T，GHANDIKOTA S，et al. Mucosal genomics implicate lymphocyte activation and lipid metabolism in refractory environmental enteric dysfunction[J]. Gastroenterology，2021，160（6）：2055-2071.
[73] GLASS C K，OLEFSKY J M. Inflammation and lipid signaling in the etiology of insulin resistance[J]. Cell Metab，2012，15（5）：635-645.
[74] COLE J B，FLOREZ J C. Genetics of diabetes mellitus and diabetes complications[J]. Nat Rev Nephrol，2020，16（7）：377-390.
[75] TOMIC D，SHAW J E，MAGLIANO D J. The burden and risks of emerging complications of diabetes mellitus[J]. Nat Rev Endocrinol，2022，18（9）：525-539.
[76] PRATLEY R E，ARODA V R，LINGVAY I，et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes（SUSTAIN 7）：a randomised，open-label，phase 3b trial[J]. Lancet Diabetes Endocrinol，2018，6（4）：275-286.
[77] RODBARD H W，LINGVAY I，REED J，et al. Semaglutide added to basal insulin in type 2 diabetes（SUSTAIN 5）：a randomized，controlled trial[J]. J Clin Endocrinol Metab，2018，103（6）：2291-2301.
[78] ARODA V R，AHMANN A，CARIOU B，et al. Comparative efficacy，safety，and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes：insights from the SUSTAIN 1-7 trials[J]. Diabetes Metab，2019，45（5）：409-418.
[79] BALLANTYNE C M，BANACH M，MANCINI G B J，et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia：a randomized，placebo-controlled study[J]. Atherosclerosis，2018，277：195-203.
[80] LAUFS U，BANACH M，MANCINI G B J，et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance[J/OL]. J Am Heart Assoc，2019，8（7）：e011662[2023-02-20]. https://doi.org/10.1161/JAHA.118.011662.
[81] GOLDBERG A C，LEITER LA，STROES E S G，et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease：the CLEAR wisdom randomized clinical trial[J]. JAMA，2019，322（18）：1780-1788.
[82] RAY K K，BAYS H E，CATAPANO A L，et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol[J]. N Engl J Med，2019，380（11）：1022-1032.
[83] NISSEN S E，LINCOFF A M，BRENNAN D，et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients[J]. N Engl J Med，2023，388（15）：1353-1364.
[84] MORROW M R，BATCHULUUN B，WU J H，et al. Inhibition of ATP-citrate lyase improves NASH，liver fibrosis，and dyslipidemia[J]. Cell Metab，2022，34（6）：919-936.